The dengue virus, transmitted by the Aedes aegypti mosquito, may be counting down to its last days due to the vaccine that has recently been approved in 11 countries.
Dengue strongly affects countries and regions that are located under 2,200 meters above sea level. These are the environments where this vector, the mosquito, lives; which is also the vector that is responsible for causing Zika and Chikungunya, which causes muscle pain and other symptoms that can lead to a deadly hemorrhagic fever.
In declarations taken from the EFE news agency, Carlos Molina states, “This is a historical event. We finally have a dengue vaccine that is 65.6% effective.” Dr. Molina is the Medical Manager for the dengue vaccine for the Andean Community, from Sanofi Pasteur.
According to the expert doctor, the vaccine can be administered to people between ages 9 and 45 and, “…is capable of preventing two of every three cases of dengue, eight of every 10 hospitalizations, and nine of every 10 serious cases of hemorrhagic dengue.”
Dr. Molina explains that it took nearly 20 years for this vaccine to be developed and involved trials with 29,000 people from Asian and Latin American countries such as Mexico, Honduras, Colombia, Brazil and Puerto Rico.
The World Health Organization (WHO) recommends that this vaccine be widely used in countries where dengue is endemic, and where the transmission and recurrent outbreaks of the disease are high.
According to figures from WHO, between 50 and 100 million people throughout the world contract this disease annually. Of these cases, 500,000 are cases of hemorrhagic dengue and 22,000 people die from it.